Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo controlled pilot study, is to determine whether this medication alleviates menopausal symptoms in women with MS. The investigators will secondarily determine whether addressing menopausal symptoms ameliorates MS symptoms and, on MRIs, is not triggering worsening inflammation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Hot Flash Related Daily Interference Scale (HFRDIS) Score
Timeframe: Baseline and 8 weeks
Change in Number of Participants Who Experienced a Reduction in Hot Flashes Per 24 Hours From Baseline to 8 Weeks
Timeframe: Baseline and 8 weeks
Change in Average Hot Flashes Per Day From Baseline to 8 Weeks
Timeframe: Baseline and 8 weeks
Number of Participants Reporting Side Effects on the Treatment Satisfaction Questionnaire for Medication (TSQM)
Timeframe: 8 weeks
Change in the Expanded Disability Status Scale (EDSS)
Timeframe: Baseline and 8 weeks